Alkixen 250MG (Crizotinib)
Product Name : Alkixen (Crizotinib)
Generic Name : Crizotinib
Formulation : Capsule
Available Pack Size : 60 Capsule
Available Strengths : 250mg
Registrations : Bangladesh
Product Information
Alkixen (Crizotinib) 250mg is an oral ALK, ROS1, and MET tyrosine kinase inhibitor used to treat ALK-positive and ROS1-positive metastatic Non-Small Cell Lung Cancer (NSCLC), as well as ALK-positive systemic Anaplastic Large Cell Lymphoma (ALCL) in eligible paediatric and young adult patients. It works by inhibiting the receptor tyrosine kinases ALK, ROS1 (c-ros), MET (HGFR), and RON, blocking the abnormal signalling these genetic alterations drive in tumour cells. Alkixen was the first FDA-approved biomarker-driven therapy for both ALK-positive and ROS1-positive NSCLC. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Alkixen (Crizotinib) 250mg
| Brand Name | Alkixen (Crizotinib) |
| Generic Name | Crizotinib INN |
| Drug Class | ALK / ROS1 / MET Tyrosine Kinase Inhibitor |
| Available Strength | 250mg |
| Formulation | Capsule |
| Pack Size | 60 Capsules per Pack |
| Primary Indication | ALK-Positive and ROS1-Positive Metastatic NSCLC; ALK-Positive Systemic ALCL |
| Regulatory Approvals | USFDA Approved (ALK+/ROS1+ NSCLC; ALK+ ALCL). EMA Approved (ALK+/ROS1+ NSCLC). |
| Originator Brand | Xalkori by Pfizer |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store below 30 degrees Celsius, in a cool, dry place. Protect from light. Keep out of the reach of children. |
How Alkixen (Crizotinib) Works
Alkixen contains Crizotinib, a small-molecule inhibitor that selectively targets several related receptor tyrosine kinases, including ALK (anaplastic lymphoma kinase), ROS1 (c-ros), MET (hepatocyte growth factor receptor, HGFR), and RON. In certain cancers, genetic rearrangements fuse the ALK or ROS1 gene to another gene, producing an abnormal, continuously active fusion protein that drives uncontrolled tumour cell growth.
By inhibiting these fusion kinases, Alkixen blocks the downstream signalling responsible for tumour proliferation and survival. Alkixen was the first FDA-approved biomarker-driven therapy available for both ALK-positive and ROS1-positive metastatic NSCLC, and historically has been the only approved treatment specifically for ROS1-positive NSCLC.
Alkixen is taken as a twice-daily oral capsule, and treatment is only appropriate for patients whose tumours have been confirmed to carry an eligible ALK or ROS1 alteration, using an approved diagnostic test.
Indications for Alkixen (Crizotinib)
Alkixen (Crizotinib) is indicated for the following conditions:
|
ALK-Positive Metastatic NSCLC For patients with metastatic non-small cell lung cancer whose tumours are ALK-positive, as detected by an approved test. |
ROS1-Positive Metastatic NSCLC For patients with metastatic non-small cell lung cancer whose tumours are ROS1-positive, as detected by an approved test. |
|
ALK-Positive Systemic Anaplastic Large Cell Lymphoma (ALCL) For paediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic ALK-positive ALCL. Safety and efficacy have not been established in older adults with relapsed or refractory systemic ALK-positive ALCL. |
|
Benefits of Alkixen (Crizotinib) 250mg
|
First Dual-Biomarker NSCLC Therapy Alkixen was the first FDA-approved therapy for both ALK-positive and ROS1-positive NSCLC, and historically the only approved option specifically for ROS1-positive disease. |
Long-Established Clinical Track Record As one of the earliest ALK inhibitors approved for NSCLC, Crizotinib has an extensive, well-characterised body of clinical evidence supporting its use. |
Extends to Paediatric ALCL Beyond lung cancer, Alkixen also offers a targeted option for children and young adults with relapsed or refractory, ALK-positive systemic ALCL. |
|
Affordable Alternative to Xalkori Alkixen contains the same active ingredient as Xalkori by Pfizer, at a significantly lower cost, making targeted ALK/ROS1-inhibitor therapy more financially accessible. |
Alternative Manufacturer Available Mediaid Pharmacy also stocks Crizonix, the same active ingredient manufactured by Beacon Pharmaceuticals, giving buyers a choice of supplier for this molecule. |
cGMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under cGMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Alkixen capsules. |
How to Take Alkixen (Crizotinib)
Route: Oral, with or without food. Capsules should be swallowed whole.
Standard dose for NSCLC: 250mg (one capsule) taken orally twice daily, until disease progression or until no longer tolerated by the patient, exactly as directed by the prescribing oncologist.
Dosing for ALCL: Dosing for paediatric and young adult patients with ALK-positive ALCL follows a specific, body-surface-area-based schedule determined by the treating paediatric oncologist; the recommended dose has not been established for patients with a body surface area below 0.60m².
Missed dose: If a dose is missed, take it unless it is less than 6 hours until the next scheduled dose, in which case skip the missed dose and resume the normal schedule.
Dose reduction for toxicity: Dose interruption and/or reduction may be needed to manage adverse reactions such as hepatotoxicity, QT prolongation, or bradycardia, according to defined dose-reduction steps directed by the prescribing physician.
Renal impairment: No starting dose adjustment is needed for mild (CrCl 60-89 mL/min) or moderate (CrCl 30-59 mL/min) renal impairment. For severe renal impairment (CrCl below 30 mL/min) not requiring dialysis, the recommended dose is 250mg orally once daily.
Paediatric use (NSCLC): The safety and effectiveness of Alkixen in paediatric patients with NSCLC have not been established; paediatric use is limited to the ALCL indication described above.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Alkixen treatment. Your oncologist will check liver function tests monthly for the first 2 months and periodically thereafter, and will monitor for new or worsening respiratory symptoms suggestive of pneumonitis. Monitoring also includes ECG and electrolytes for QT interval prolongation, heart rate for bradycardia, and periodic eye examinations for visual disturbances. Report any yellowing of the skin or eyes, breathlessness, cough, fever, dizziness, palpitations, fainting, or significant vision changes to your doctor immediately.
Drug Interactions and Important Information
Crizotinib is predominantly metabolised by CYP3A and is a substrate for P-glycoprotein (P-gp) in vitro. Avoid concomitant use of strong CYP3A inhibitors; if unavoidable, reduce the Alkixen dose to 250mg orally once daily. Avoid concomitant use of strong CYP3A inducers, as these may reduce Crizotinib effectiveness. Avoid grapefruit and grapefruit juice during treatment.
Use caution when combining Alkixen with other medicines that slow heart rate or prolong the QTc interval. Women of childbearing potential should use effective contraception during treatment and for at least 90 days after the final dose; men with partners of childbearing potential should also use effective contraception during this period. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Alkixen.
Side Effects and Precautions
|
Common Side Effects Visual disturbances Nausea, diarrhoea, and vomiting Oedema (swelling) and constipation Elevated liver enzymes Fatigue and decreased appetite Upper respiratory tract infection Dizziness and neuropathy |
Serious Warnings and Precautions Hepatotoxicity, including cases of significant liver injury requiring dose adjustment. Interstitial lung disease/pneumonitis, which can be fatal. QT interval prolongation and bradycardia. Severe visual loss (rare) and gastrointestinal perforation. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Alkixen (Crizotinib)?
Alkixen is suitable for adult patients with ALK-positive or ROS1-positive metastatic NSCLC, confirmed by an approved biomarker test, and for paediatric patients aged 1 year and older and young adults with relapsed or refractory, ALK-positive systemic ALCL. It is prescribed by medical oncologists and paediatric oncologists experienced in biomarker-guided cancer therapy. A thorough medical assessment including ALK/ROS1 testing, baseline liver function, cardiac evaluation (ECG), and eye examination is required before initiating treatment.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Alkixen under cGMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Alkixen is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Xalkori by Pfizer at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Alkixen (Crizotinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Alkixen (Crizotinib) from Mediaid Pharmacy?
Alkixen represents a foundational, well-established option in the treatment of ALK-positive and ROS1-positive lung cancer, as well as ALK-positive ALCL. As the generic equivalent of Xalkori by Pfizer, it delivers the same active ingredient, Crizotinib, with the same proven, multi-target kinase inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under cGMP-compliant standards and distributed globally by Mediaid Pharmacy, Alkixen gives patients worldwide access to advanced biomarker-driven cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Crizotinib option with worldwide delivery, Alkixen from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Alkixen (Crizotinib)
What is Alkixen (Crizotinib) used for?
Alkixen (Crizotinib) is used to treat adult patients with ALK-positive or ROS1-positive metastatic non-small cell lung cancer, and paediatric patients aged 1 year and older and young adults with relapsed or refractory ALK-positive systemic Anaplastic Large Cell Lymphoma. It works by blocking the abnormal ALK, ROS1, and related kinase signalling that drives these specific, genetically-defined cancers.
How should I take Alkixen (Crizotinib)?
For NSCLC, Alkixen is taken orally, twice daily, with or without food. The standard dose is 250mg (one capsule) twice daily. Dosing for the ALCL indication is body-surface-area-based and determined by a paediatric oncologist. Always follow your oncologist’s exact instructions.
What strength is Alkixen available in?
Alkixen is available in a 250mg capsule, supplied in a pack of 60 capsules, providing approximately a 30-day supply at the standard 250mg-twice-daily dose for NSCLC.
Is Alkixen the same as Xalkori (Crizotinib by Pfizer)? Is it the same as Crizonix?
Yes. Alkixen is the generic equivalent of Xalkori, and contains the same active ingredient, Crizotinib, as Crizonix, another crizotinib brand also available from Mediaid Pharmacy. Alkixen is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, while Crizonix is manufactured by Beacon Pharmaceuticals; both offer the same clinical mechanism as Xalkori at a significantly lower cost.
What are the side effects of Alkixen (Crizotinib)?
Common side effects include visual disturbances, nausea, diarrhoea, vomiting, swelling, and fatigue. Serious but less common risks include liver injury, lung inflammation, QT interval changes, slow heart rate, and severe vision loss. Always consult your oncologist for a complete assessment of your individual risks and benefits before starting treatment.
Can Alkixen be used with other medications?
Alkixen should not be combined with strong CYP3A inducers, and requires a dose reduction if a strong CYP3A inhibitor cannot be avoided. Avoid grapefruit products, and use caution with medicines that slow heart rate or affect the QT interval. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Alkixen.
Is Alkixen (Crizotinib) safe during pregnancy or breastfeeding?
No. Alkixen is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Effective contraception should be used during treatment and for at least 90 days after the final dose, by both female patients and male patients with partners of childbearing potential. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Alkixen (Crizotinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Alkixen (Crizotinib) 250mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Alkixen (Crizotinib) 250mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
